Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01543230 · ClinicalTrials.gov registry record · NA
CoMplete™ Acetabular Hip System
A NA study, sponsored by DePuy Orthopaedics.
- Terminated
- Registry status
- NA
- Development phase
- 58
- Enrollment target
NCT01543230: Clinical Trial NA study, sponsored by DePuy Orthopaedics.
NCT01543230 is a NA study that was terminated before completion, run by DePuy Orthopaedics. The registered enrollment target is 58 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01543230, a NA study, was terminated before completion, sponsored by DePuy Orthopaedics.
- TERMINATED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
Study Summary
The primary objective of this investigation is to evaluate survivorship at ten years. For this post approval study (PAS), a maximum acceptable hazard of revision is assumed to be a constant 1% per year.
Primary Outcome
Subjects will be seen each year through year 5 postoperatively for radiographic and clinical follow-up, and then at 8 and 10 years postoperatively for radiographic and clinical follow-up. Survivorship means the removal of either or both of the components (ceramic head or metal liner).
Interventions
- DEVICE Total hip replacement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-10 |
| Phase | NA |
Why NCT01543230 stopped before completion
NCT01543230 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Total hip replacement is the first listed.
NCT01543230 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01543230 about?
NCT01543230 is a clinical study titled "CoMplete™ Acetabular Hip System". The primary objective of this investigation is to evaluate survivorship at ten years. For this post approval study (PAS), a maximum acceptable hazard of revision is assumed to be a constant 1% per year.
What is the current status of trial NCT01543230?
This trial is currently terminated. It is a NA study. The enrollment target is 58 participants. The study started on 2012-02. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01543230?
The interventions under investigation include: Total hip replacement (DEVICE).
Who is sponsoring clinical trial NCT01543230?
This trial is sponsored by DePuy Orthopaedics, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01543230's enrollment target sits among peer trials
58 1256th of 2000 higher than 740 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia